Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.

ABSTRACT:

SUBMITTER: Pantaleo G 

PROVIDER: S-EPMC7156919 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature